Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype
- 4 June 2021
- journal article
- research article
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 97 (7) , 943-957
Abstract
PURPOSE Herein we describe the in vitro and in vivo activity of FK228 (Romidepsin), an inhibitor of class I HDACs, in counteracting and radiosensitizing embryonal (ERMS, fusion-negative) and alveolar (ARMS, fusion-positive) rhabdomyosarcoma (RMS). METHODS RH30 (ARMS, fusion-positive) and RD (ERMS, fusion-negative) cell lines and human multipotent mesenchymal stromal cells (HMSC) were used. Flow cytometry analysis, RT-qPCR, western blotting and enzymatic assays were performed. Irradiation was delivered by using an x-6 MV photon linear accelerator. FK228 (1.2 mg/kg) in vivo activity, combined or not with radiation therapy (2 Gy), was assessed in murine xenografts. RESULTS Compared to HMSC, RMS expressed low levels of class I HDACs. In vitro, FK228, as single agents, reversibly downregulated class I HDACs expression and activity, and induced oxidative stress, DNA damage and a concomitant growth arrest associated to PARP-1-mediated transient non-apoptotic cell death. Surviving cells upregulated the expression of cyclin A, B, D1, p27, Myc and activated PI3K/Akt/mTOR and MAPK signaling, known to be differently involved in cancer chemoresistance. Interestingly, while no radiosensitizing effects were detected, in vitro or in vivo, on RD cells, FK228 markedly radiosensitized RH30 cells by impairing antioxidant and DSBs repair pathways in vitro. Further, FK228 when combined with RT in vivo significantly reduced tumor mass in mouse RH30 xenografts. CONCLUSION FK228 did not show antitumor activity as single agent whilst its combination with RT resulted in radiosensitization of fusion-positive RMS cells, thus representing a possible strategy for the treatment of the most aggressive RMS subtype.Keywords
Funding Information
- AIRC (24696)
- the University of Roma, Sapienza
This publication has 67 references indexed in Scilit:
- BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cellsCancer Letters, 2020
- Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasisEMBO Reports, 2019
- Preclinical rationale for entinostat in embryonal rhabdomyosarcomaSkeletal Muscle, 2019
- Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell LinesRadiation Research, 2016
- Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell populationMolecular Cancer, 2016
- BCL2 Suppresses PARP1 Function and Nonapoptotic Cell DeathCancer Research, 2012
- HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphomaBlood, 2011
- Histone acetylation: a switch between repressive and permissive chromatinEMBO Reports, 2002
- Cyclin D1 Overexpression versus Response to Induction Chemotherapy in Squamous Cell Carcinoma of the Head and Neck—Preliminary ReportActa Oncologica, 2001